Drug firm Ranbaxy Laboratories Ltd’s March quarter financials benefited from sharply higher US sales, one-time income from settlements and favourable foreign exchange movements. This quarter’s performance will be a difficult feat to repeat in calendar 2010. Still, Ranbaxy is likely to overtake its profit guidance of Rs450 crore for the year, barring unforeseen events. In the March quarter, on a consolidated basis, Ranbaxy’s overseas sales rose 74% to Rs2,082 crore, while sales in India rose 12% to Rs408 crore. On a constant currency basis, sales rose by around 65%.
Also Read | Hindalco Industries sees strong growth prospects
In the US market, Ranbaxy got the full benefit of the generic Valtrex’s sales, with market share going up to 64%. It also launched an authorized generic version of Oxycodone ER. US market sales, as a result, rose nearly fourfold to Rs1,151 crore. Growth in other markets except for Asia Pacific was also good. On a sequential basis, overall sales rose 9.7% and US sales rose 52%. Another important contributor to operating income was the Flomax settlement, which netted Ranbaxy around $50 million (Rs225.5 crore).
Graphic: Yogesh Kumar/Mint
Excluding the effect of forex-related movements, Ranbaxy’s operating profit margin was 38% compared with 0.1% in the year-ago period. Some of this is attributable to its restructuring efforts, but a lot to the effect of US sales and settlement income. Maintaining this margin will be difficult during the rest of the year. Forex-related gains during the March quarter amounted to Rs449 crore compared with a loss of Rs1,130 crore in the year-ago period. Thus, forex gains contributed to nearly one-third of pre-tax profits. Still, with a net profit of Rs961 crore, Ranbaxy has crossed its annual guidance in the first quarter, even after excluding forex gains. Any major volatility in forex rates could impact its results in the rest of the year.
It has entered into a settlement with Takeda Pharmaceutical Co. Ltd for launching generic Actos in the current quarter. The company is also expecting its base business to maintain growth during 2010. It is investing heavily in its Indian operations. But India’s sales growth at 15% underperformed the market. In 2010, investor focus will centre on its ability to resolve its pending plant compliance issues with the US Food and Drug Administration (FDA), at least for its Dewas plant. To its credit, Ranbaxy’s US operations are in a much better shape despite its regulatory issues. A patch-up with the FDA, however, will see its US business achieve its full potential.
The share rose 3.5% before ending the day up by only 0.9%, probably due to the role of forex gains in profit growth. Apart from the FDA issue, any further settlements with innovator firms or first-to-file opportunities, better performance from its Indian business and visible benefits from its association with Daiichi-Sankyo will be some growth triggers to watch out for.
Write to us at email@example.com